← Back to patent-cliff list
Staccato Alprazolam(Engage )
Tier C — Watch / tradeStaccato Alprazolam(Engage )
Engage Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：GABAAR
Brand：Alprazolam Staccato
Indications (approved)：Epilepsy, Seizure, Asthma
Regional status
US
Phase III
2022-01-11
EU
Phase III
2022-01-11
China
Phase III
2022-11-09
Japan
Phase III
2022-01-11
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Staccato Alprazolam(Engage )?
Approved indications include: Epilepsy, Seizure, Asthma.
When does the Staccato Alprazolam(Engage ) patent expire?
No public expiry year is available for Staccato Alprazolam(Engage ) yet; this page updates once verified.
How do I get a quote for Staccato Alprazolam(Engage ) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21